Fluoroquinolone prescribing for diabetic foot infections following an FDA Drug Safety Communication for aortic aneurysm risk

Link to article at PubMed

Antimicrob Agents Chemother. 2021 Jun 28:AAC0070821. doi: 10.1128/AAC.00708-21. Online ahead of print.


In 2018, the United States Food and Drug Administration (FDA) issued a Drug Safety Communication regarding fluoroquinolone-associated aortic aneurysm. This quasi-experimental study assessed antibiotic prescribing for 198 hospitalized patients with diabetic foot infection. Following the warning, median inpatient fluoroquinolone days of therapy (DOT) decreased from 3 to 0 days (P < 0.001), corresponding with increased beta-lactam DOT and OPAT enrollment. FDA communications may influence antibiotic selection and transitions of care, representing opportunities for antimicrobial stewardship.

PMID:34181481 | DOI:10.1128/AAC.00708-21

Leave a Reply

Your email address will not be published.